

Special Issue

Molecular Imaging in Oncology: Recent Advances

Message from the Guest Editor

Nuclear medicine and molecular imaging thrive under continuous change. Molecular imaging is a technique that facilitates the non-invasive imaging of molecular targets. In the current decade, a wave of new theranostic compounds, targeting the same receptor for imaging and therapy, will change the oncology therapeutic arsenal. The rapid development of quantitative molecular imaging (PET and SPECT), combined with high-level abilities in cross-sectional morphological imaging (CT and MRI), has excavated exciting opportunities. This way, the field of nuclear medicine has rejuvenated itself repeatedly. This Special Issue highlights the hot topics of the molecular imaging tracer principle, which provides rich soil for scientific discovery, clinical diagnosis, treatment response monitoring, image-guided decision making, precision medicine and personalized medicine, non-invasive tissue characterization, the development of new tracers and imaging biomarkers, the development of (radiomics-based) prediction tools, artificial intelligence, deep learning, Big Data, targeted radionuclide therapies, and personalized dosimetry.

Guest Editor

Prof. Dr. Lioe-Fee de Geus-Oei

Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands

Deadline for manuscript submissions

15 September 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/146714

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)